A protein that can specifically bind to mutated forms of huntingtin and prevent its production — while preserving the normal versions of this protein — may represent a new strategy to attack Huntington’s disease. Researchers from Sangamo and Shire are going to present results from preclinical studies of…
“The Talk” has a very different meaning to most people than it does in our home. When our daughter was born, my wife, Jill, had a very clear wish that we would always be open and honest with our daughter about things. By “things,” Jill meant most everything. She wanted…
I’m sure the headline of this column made you look twice. No, that’s not a typo. You might be saying right now: “How could anything associated with Huntington’s disease make my life better?” I get it. I understand firsthand what a horrible condition Huntington’s disease (HD) is. It’s not…
Although many patients with Huntington’s disease (HD) experience pain, they report this problem has less of an effect on their daily lives than it does for the general population, a review study has found. Due to the areas of the brain affected in Huntington’s, patients…
Second in a series. Read part one. Based on the number of television commercials touting DNA testing, finding out information about one’s genes has become de rigueur these days. As I mentioned in my last column, however, when there’s the possibility of having inherited genes that might cause…
DYST 201, a gene therapy targeting the mutated forms of the gene responsible for Huntington’s disease, has shown promising results, Dystrogen Therapeutics announced. The results will be presented at two meetings in Krakow, Poland — the July 6-11 44th FEBS Congress and the June 11-16 24th Annual Meeting of the RNA Society.
Sometimes it can seem like everyone wants to give you advice about how you should live your life or what you should do to feel and remain healthy. Now that I write this, you could say this column is doing the same thing! Here’s a quote that amused me: “I’ll…
The U.S. Food and Drug Administration (FDA) has given fast track designation to AMT-130, uniQure’s gene therapy candidate for the treatment of Huntington’s disease. The designation helps to speed the development, testing, and review of therapies for serious diseases with high unmet medical need. “Achieving Fast Track Designation from the…
First in a series. I wanted to write a positive column this week about the strength and courage my wife has displayed over the last few months. She has, and I will — but not this week. In fact, welcome to the first of two parts about a topic that…
Aiming to raise awareness about Huntington’s disease (HD) while also commemorating a decade of community service, HD Reach presented its annual Education Day April 6 in Raleigh, North Carolina. Themed “Looking Back, Reaching Forward,” the event was held at the McKimmon Center at North Carolina State University. The non-profit…
Get regular updates to your inbox.
